TAC-T
TAC-O
For use with suture anchors
SOLE RECIPIENT OF THE 2024 AOSSM ACE AWARD
Biologic solutions to optimize enthesis reformation, EnFix is the future of bone to tendon healing.
IT’S ALL ABOUT THE ENTHESIS™
EnFix® is specifically designed to address Enthesis Failure Syndrome by promoting the remodeling of tissue approximating that of the natural bone-tendon enthesis.
Our technology has a successful clinical legacy and has been extensively studied in bone and tendon healing demonstrating both osteoconductivity and osteoinductivity. The demineralized bone fibers in EnFix® promote optimal biologic performance while easily integrating into current surgical techniques.
The Bone Textile™ technology yields long and strong fibers that promote cell wicking, cell adhesion and cell proliferation, versus the highly variable short shavings that are produced by other processes. The FormLok™ technology imparts shape retention to the device, even when immersed in liquid, as is often required for use in arthroscopic surgery.
Andy Carter, PhD.
Co-Founder and Chief Technology Officer,
Tetrous, Inc.
Nik Verma, MD.
Professor and Director
Sports Medicine and Shoulder
Midwest Orthopedics at Rush
Head Team Physician,
Chicago White Sox
Ferdinand “Tito” Liotta, MD.
Orthopedic Surgeon & Sports Medicine Physician
Valley View Health
Glenwood Springs, CO
In the United States alone, more than 500,000 rotator cuff repairs (RCR) are performed annually at a cost of $3 billion.
20% to 70% of RCRs structurally fail. This failure rate is likely to rise given an aging population with greater functional demands.
Most augmentation products have focused on overlays / patches to reinforce the tendon.
The enthesis is where failures often occur in sports medicine repairs. Tendon reattachment to the bone is a crucial clinical need, especially in larger tears, since failure rates increase linearly with tear size.